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At the end of 2019, the SARS-COV-2 virus was observed to cause respiratory 
disease, and it is responsible for the high number of patients admitted to hospital. 
Many biopharmaceutical / biotechnology companies have started manufacturing 
vaccines that can prevent the SARS-COV-2 virus. An important issue is COVID-19 
vaccine stability, one of the most frequently stated problems faced through 
vaccination programs particularly in the high temperatures low-income countries. 
Along with cost, availability, and delivery – stability makes delivery simple. This 
review analyses the characteristics of the two common groups of COVID-19 
vaccines – Adenovirus based (such as the Oxford/AstraZeneca and Janssen 
vaccines) and mRNA based (such as Pfizer/BioNTech and Moderna) – and in 
particular the potential application of human serum albumin (HSA) as a stabiliser for 
the mRNA COVID-19 platform.  
 
From the stability point of view, while the Adenoviral vector-based vaccines can be 
stabilised and stored at 2–8 °C range yielding 6 months shelf-life, the mRNA-based 
vaccines have to be stored at much lower temperatures, limiting their distribution to 
the higher temperature regions. This emphasise the importance of research into 
formulation solutions, such as the use of excipients like human serum albumin, to 
improve these products stability and, therefore facilitate vaccination programs 
without the need for cold chain storage. The availability of these vaccines to low-
income countries would have a major role in lowering the cases of COVID-19 
infections. In future investigations, it is possible to look at different unstable COVID-
19 platforms by applying new technologies for making a stabilise vaccine.
 V 
Abbreviations  
                           
Ad26                            Adenovirus type 26  
AEX-HPLC                  Anion exchange high performance liquid chromatography 
ALC-0159               2[(polyethylene glycol)-2000]-N,N- ditetradecylacetamide 
ALC-0315                   
AVV                            Adenoviral Vector 
BNT162b2                  Pfizer/BioNTech vaccine platform 
ChAdOx1                    Chimpanzee adenovirus-vectored vaccine  
COVID-19                   Coronavirus disease 
Cov2.S                        Encoding SARS-COV-2 spike glycoprotein 
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ddPCR                        Droplet Digital polymerase chain reaction 
DNA                            Deoxyribonucleic acid    
DSPC                         1,2-Distearoyl-sn-glycero-3-phosphocholine 
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ELISA                         Enzyme-linked Immunosorbent Assay 
HBCD                         2-hydroxypropyl-β-cyclodextrin    
HEK                            Human embryonic kidney  
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ID-PCR                       Identity polymerase chain reaction                         
kDa                             Kilodaltons 
LAV                            Live Attenuated Virus  
LC-UV/MS                  Liquid Chromatography–Ultraviolet/Mass Spectrometry 
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mg                              Milligram 
mRNA                        Messenger RiboNucleic Acid 
mRNA-1273              Moderna vaccine platform 
nCoV-19                    Expressed SARS-CoV-2 spike protein 
NGS                           Next Generation Sequencing 
PCR                           Polymerase chain reaction 




PEG                      Polyethylene glycol/macrogol 
PEG2000-DMG       1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000  
QPA                         Quantitative PCR based potency assay 
qPCR                       Quantitative polymerase chain reaction 
RNA                         Ribonucleic acid   
RP-HPLC                 Reversed phase high performance liquid chromatography 
RP-UPLC                Reversed-phase ultra-high-performance chromatography 
RT-PCR                   Reverse transcription polymerase chain reaction 
SARS-COV-2          Sever Acute Respiratory Syndrome Coronavirus 2  
S protein                  Spike protein  
TGE-ELISA             Transgene expression enzyme-linked immunosorbent assay  
μg                            Microgram 
UTR                         Untranslated region 
UV spectroscopy     Ultraviolet spectroscopy 
VLP                          Virus-Like Particle   
VP-qPCR                 Viral particle-quantitative polymerase chain reaction 
VVr + APC               Viral Vector replicating + Antigen Presenting Cells 
VVr                           Viral Vector replicating      
VVnr + APC             Viral Vector non-replicating + Antigen Presenting cells 
VVnr                        Viral Vector non-replicating 
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CHAPTER 1  
 
The model of stabilised COVID-19 vaccine: Adenoviral 
vector platform  
       Human pathogens identified as Coronaviruses (CoV) have been known since 
the 1960s (Kahn and McIntosh 2005). At the end of 2019, in Wuhan Hubei China, 
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) was observed 
causing pneumonia among patients (Guo et al. 2020; Krammer 2020; Tian et al. 
2020). The SARS-COV-2 virus is responsible for the current pandemic (Guo et al. 
2020; Krammer 2020; Tian et al. 2020). The Latin name of ‘corona’ means halo or 
crown. Indeed, the surface characteristics of the virion have a crown-like shape in 
appearance under the electron microscope (European Centre for Disease 
Prevention and Control 2021). The SARS-COV-2 is an enveloped virus (Huang et al. 
2020; Qamar et al. 2020) with 65 –125 nm in diameter, and it contains single-
stranded RNA (Astuti and Ysrafil 2020).  
 
Since the outbreak, there has been a huge attempt worldwide to develop COVID-19 
vaccine as a response to Coronaviruses pandemic. Its development is a crucial 
approach, which in a role can alleviate the burdens of the virus on society, economy 
and public health (Krammer 2020). According to the World Health Organisation 
(2021e) report, there are 10 candidate approaches of “platforms” in the clinical trial 
phase, which can work against the SARS-COV-2 virus. These are diverse and based 
on a variety of approaches such as: Deoxyribonucleic acid, Protein Subunits, 
Inactivated Virus, Virus-Like Particle (VLP), Live Attenuated Virus (LAV), Viral Vector 
replicating with the Antigen Presenting Cells (VVr + APC), Viral Vector non-
replicating with the Antigen Presenting Cells (VVnr + APC), Viral Vector replicating 
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One of the key important aspects of the COVID-19 vaccine platforms is stability, 
which can be a challenge for some biopharmaceutical companies. The cold chain 
storage requirements for the COVID-19 vaccine cause a logistic issue (World Health 
Organisation 2021g), which affects the immunisation programme quality, especially 
in low-income countries due to the low-temperature control (Park et al. 2021). 
Albumedix is a Nottingham based biopharmaceutical company which manufacturers 
a recombinant version of human serum albumin (HSA) protein, which is used to 
stabilise a wide range of active pharmaceutical ingredients and biopharmaceuticals 
such as peptides, proteins, vaccines and is also used in cell therapy processing. 
Human serum albumin is a well-known excipient and is used for a large number of 
regulatory-approved pharmaceuticals worldwide. This review will consider the 
current published knowledge around selected COVID-19 vaccine platforms. We will 
first show the model of stabilised COVID-19 vaccine for the Adenoviral Vector 
platform such as Oxford/AstraZeneca and Janssen. Then, we will highlight the model 
of un-stabilised COVID-19 vaccine for the mRNA platform such as Pfizer/BioNTech 
and Moderna. Finally, we will discuss the potential application of human serum 
albumin as a potential stabiliser for vaccines in general and for the mRNA platform in 
particular.    
1.1 Introduction 
       Adenoviral vector (AVV) has emerged as a powerful platform that has been 
employed against infectious diseases (Guo et al. 2018). It is a diverse family of 
viruses that belongs to more than 50 serotypes called adenoviridae (Singh et al. 
2019). In mammalian hosts, it can induce adaptive and innate immune responses 
(Tatsis and Ertl 2004). In 1953, Rowe and colleagues were the first to discover the 
AVV platform (Rowe et al. 1953). Additionally, the AVV can be genetically modified 
with foreign antigens, which can elicit T cells and specific antibody responses in 
hosts (Guo et al. 2018). In Cheng et al. (2015) article, it was shown that the AVV is a 
double-stranded DNA virus, non-enveloped and icosahedral in shape, which can 
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Nowadays, there has been an increasing interest in using AVV as a platform against 
the SARS-COV-2 virus. This chapter will emphasise the Oxford/AstraZeneca and 
Janssen AAV platforms, which are examples of stabilised AAV platform.  
 
       1.1.1 Introduction to Oxford/AstraZeneca COVID-19 vaccine 
produced using Adenoviral vector platform   
 
The ChAdOx1 nCoV-19 vaccine is manufactured by the University of Oxford and 
AstraZeneca, a UK pharmaceutical company. Two methods are used in AVV 










Figure (1): Adenoviral vector used two methods in vaccine manufacturing by 
inserting the spike gene. (A) Replication-competent vector. (B) Replication-
incompetent vector - adapted from Krammer (2020 p.520 fig.3). 
 
The replication-competent vector (Figure1, A) expresses the virus spike protein and 
propagates in the vaccinated cells. However, the replication-incompetent vector 
(Figure1, B) articulates the virus spike protein but cannot propagate in the 
vaccinated cells. Accordingly, ChAdOx1 nCoV-19 vaccine used the replication-
incompetent vector, which is based on the engineered chimpanzee Adenoviral vector 
virus to express the SARS-CO-2 virus spike protein; by disabling the virus from 
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       1.1.2 Introduction to Janssen COVID-19 vaccine made using 
Adenoviral vector platform  
 
The Ad26.Cov2.S vaccine is manufactured by Janssen Pharmaceutical Companies. 
The Ad26.Cov2.S is a recombinant viral vector platform that uses human adenovirus 
to express the SARS-COV-2 virus spike protein (World Health Organisation 2021b). 
Indeed, it referred to a species D from adenovirus type 26 (Ad26), and it is one of the 
most common replication-incompetent vectors (Figure1, B) (Khare et al. 2011; 
Pinschewer 2017; World Health Organisation 2021b). In the European Medicines 
Agency (2021c) report, it reported that the Ad26.Cov2.S vaccine encodes the SARS-
COV-2 spike gene inside the ΔE1A/E1B region, encompassing stabilising modifiers 
after deletions in the E1 region (Figure 2). Additionally, part of the E3 region was 
removed, which is ΔE3, to create a sufficient space in the viral genome to insert the 
SARS-COV-2 spike gene. Once the Ad26.Cov2.S vaccine is injected, the cells start 









Figure (2): Adenoviral vector type 26 encoding the SARS-COV-2 virus in the 
ΔE1A/E1B region including stabilising modifications – copied from European 
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1.2 Oxford/AstraZeneca COVID-19 vaccine  
The Oxford/AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19) prevents 
SARS-COV-2 virus through the activation of an individual’s immune system – natural 
defences. This vaccine has been approved in many countries for use in those aged 
18 years and older (Medicines & Healthcare products Regulatory Agency 2021d).           
           1.2.1 The content, storage conditions and the physical state 
of the formulation  
The ChAdOx1 nCoV-19 vaccine produced using genetically modified organisms of 
the human embryonic kidney (HEK) 293 cells (Medicines & Healthcare products 
Regulatory Agency 2021a). Each dose of ChAdOx1 nCoV-19 vaccine contains viral 
particle and excipients as stated in Table 1.  
Table 1: The content of Oxford/AstraZeneca COVID-19 vaccine formulation with 
their reported concentrations (Medicines & Healthcare products Regulatory Agency 
2021a).   
*It is a recombinant, chimpanzee adenovirus vector.  
 
Oxford/AstraZeneca COVID-19 (ChAdOx1 nCoV-19) vaccine formulation 
1 dose (0.5 ml) The content of the formulation. Concentrations per dose. 
Viral particle ChAdOx1-S*.    5 × 10^10 viral particles.  
Other excipients 
 
1. L-histidine. Not reported.  
2. L-histidine hydrochloride 
monohydrate. 
Not reported. 
3. Magnesium chloride 
hexahydrate. 
Not reported. 
4. Polysorbate 80 (E433). <100 μg per dose (Turner et al. 
2021). 
5. Ethanol 95%. 2 mg (AstraZeneca 2021).  
 6 
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The content of Oxford/AstraZeneca formulation has some different viral particles and 
other excipients from Janssen such as L-histidine and L-histidine hydrochloride 
monohydrate, which provides buffering; magnesium chloride hexahydrate and 
disodium edetate dihydrate acting as a stabiliser; sucrose acts as tonicifier/stabiliser 
(European Medicines Agency 2021b). In contrast to Oxford/AstraZeneca formulation, 
however, Janssen formulation used citric acid monohydrate and trisodium citrate 
dihydrate as a buffering agent; HBCD is used instead of magnesium chloride 
hexahydrate and disodium edetate dihydrate in the Oxford/AstraZeneca formulation 
as a stabiliser.  
The knowledge of ChAdOx1 nCoV-19 vaccine storage conditions and the physical 
state is important for better understanding of AVV stability. Most vaccines should be 
kept in the refrigerator from production until the use due to their thermosensitivity. 
Ensuring vaccine stability is important for conducting immunisation programs (Clénet 
2018). Furthermore, Oxford/AstraZeneca formulation can be stored within the 2 –8 
°C range without the need to be kept at freezing temperatures. Its formulation is 
impacted by light; therefore, the vials should be kept in the outer carton. In contrast, 
Oxford/AstraZeneca formulation can be stored within the 2-25 °C range during its 
use. Once the first dose is withdrawn the other doses should be used within 6 hours 
(Medicines & Healthcare products Regulatory Agency 2021a).   
The long-term storage of ChAdOx1 nCoV-19 vaccine substance was revealed to be 
adequate, and the proposed shelf-life was 6 months (Medicines & Healthcare 
products Regulatory Agency 2021d). The vaccine colour showed colourless to a 
slightly opalescent solution (World Health Organisation 2021b).   
 
 6. Sucrose.  Not reported. 
7. Sodium chloride. <1 mmol sodium≈ 23 mg/0.5 ml 
dose + sodium-free (AstraZeneca 
2021). 
8. Disodium edetate dihydrate. Not reported. 
9. Water for injections. Not reported.  
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1.3 Janssen COVID-19 vaccine 
The Janssen COVID-19 vaccine (Ad26.Cov2.S) provokes neutralising 
antibodies in healthy individuals and has been approved for use among 18 and 55 
years old (World Health Organisation 2021c). 
      1.3.1 The content, storage conditions and the physical state of 
the formulation 
The Janssen company summarised important information about AD26.COV2.S 
formulation with their concentrations (Table 2). 
Table 2: The content of AD26.COV2.S formulation with their reported concentrations 
(World Health Organisation 2021c).   
Janssen COVID-19 vaccine (AD26.COV2.S) formulation 
1 dose (0.5 ml) The content of the 
formulation. 
Concentrations per dose. 
Viral particle AD26.COV2.S viral 
particles. 
5 × 10^10 viral particles.  
Other excipients 
 
1- Polysorbate 80 (E433). 0.16 mg/dose (Banerji et al. 2021; 
Janssen Pharmaceutical 
Companies 2021). 
2- Ethanol 95%. 2.04 mg (Janssen 
Pharmaceutical Companies 
2021). 
3- Sodium chloride. 2.19 mg (Janssen 
Pharmaceutical Companies 
2021). 
4- Citric acid monohydrate.  0.14 mg (Janssen 
Pharmaceutical Companies 
2021). 
5- Trisodium citrate 
dihydrate 





25.50 mg Janssen 
Pharmaceutical Companies 
2021). 
7- Sodium hydroxide. Not reported.  
8- Hydrochloric acid.  Not reported.  
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The content of Janssen formulation has the same viral particles and other excipients 
from Oxford/AstraZeneca platform such as sodium chloride, ethanol 95% and 
polysorbate 80 (E433) (AstraZeneca 2021; Janssen Pharmaceutical Companies 
2021; Turner et al. 2021).  
The awareness of AD26.COV2.S formulation storage conditions and physical state is 
important for a better understanding of AVV stability. Currently due to the COVID-19 
pandemic, there is a desire for a convenient and rapid distribution chain with suitable 
storage of the formulation. The convenient and rapid distribution chain could improve 
the COVID-19 vaccine stability profile, which can lead the formulation to be stored at 
the refrigerator with a low cost of manufacturing. It also minimises the logistic 
barriers that make it more accessible to patients (Crommelin et al. 2021b). Its shelf 
life is provided at −20 °C for 2 years but it can be stored within 2-8 °C range for up to 
3 months with no need for reconstitution. If the vaccine is thawed, it should not be re-
frozen again. Nevertheless, the light might affect vaccine formulation and the vials 
should be kept in the outer carton; whereas the colour of the vaccine product is 
colourless to slightly yellow, and it is an opalescent suspension in terms of the 
physical state (World Health Organisation 2021c).   
 
1.4 The strengths of Adenoviral vector platform  
 
           In vaccine development, each platform has strengths and weaknesses. This 
part intends to discuss the Adenoviral vector (AVV) strengths. Adenoviral vectors 
can affect the immune system, and their effects induce robust humoral and cellular 
immunity pathways against the introduced antigens (Haque and Pant 2020; 
Stanberry and Strugnell 2011). In regards to drug delivery, it can facilitate oral 
delivery through its application to the mucosal surface (Stanberry and Strugnell 
2011). Regarding its production, the AVV can be easily engineered (Stanberry and 
Strugnell 2011). Concerning its genetic expression, it has long-term gene expression 
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1.5 The weaknesses of Adenoviral vector platform  
 
         The Adenoviral vector (AVV) platform has weaknesses in vaccine 
development. In regards to immunity, the AVV has a potential for both lack 
attenuation and over attenuation. The pre-existing vector antibodies decrease the 
efficacy of the AVV and cause a misdirection for the immune response (Haque and 
Pant 2020; Rerks-Ngarm et al. 2009; Stanberry and Strugnell 2011). It limits the 
subsequent dose from its specific response (Stanberry and Strugnell 2011). In 
immunocompromised hosts, the Adenoviral vector causes diseases due to the 
viruses’ recombination. According to Stanberry and Strugnell (2011) clarification, the 
recombination of the AVV to remove its infectivity can restore virulence after 
attenuation. It has a probability of triggering a latent or persistent infection for some 
vectors. In terms of cost, it is expensive in large-scale manufacturing (Haque and 
Pant 2020).    
 
 
1.6 Characterisation techniques for the 
Oxford/AstraZeneca and Janssen platform 
        Oxford/AstraZeneca and Janssen have summarised the experimental 
investigation in order to characterise the chimpanzee and serotype 26 based 
Adenoviral vector platforms. The Oxford/AstraZeneca structural characteristics used 
the orthogonal analytical methods to examine the particulate matter, molar mass, 
size heterogeneity, morphology, structure/identity, and biological activity. General 
tests were performed such as polysorbate 80 content, osmolality, pH, colour, and 
appearance to test the active substance. The structure/identity characterisation 
achieved by using viral particle and the qPCR techniques. Anion exchange high-
performance liquid chromatography (AEX-HPLC) was applied in order to determine 
the concentration. The impurities were verified using a nuclease, Host Cell Protein, 
and residual DNA. The safety tests were done for endotoxin and bioburden 
purposes. Moreover, to determine the drug product and substance infectivity, a cell-
based infectivity assay was applied (European Medicines Agency 2021b).   
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According to the European Medicines Agency (2021c) report, Janssen 
characterisation studies were conducted  to investigate the structure-function 
relationships, biological activity, viral DNA, particle heterogeneity and capsid 
composition of the formulation. To highlight the biological activity, the transgene 
expression enzyme-linked immunosorbent assay (TGE-ELISA) was used to measure 
the relative level of transgene expression. Moreover, in an attempt to determine the 
infectivity in release testing, the quantitative PCR is based on the potency assay 
(QPA), which has a strong relation with the TGE-ELISA. The virus DNA 
characterisation technique was used to confirm the flanking regions and the 
transgene identity. The forced degradation studies such as the thermal stress are 
applied to study the structure/function relationship of the Janssen platform. The 
Janssen platform impurities were characterised using downstream buffer 
components, PER.C6 TetR host cell constituents, additives, and cell culture media 
components. Chromatography can be used in the purification process for impurity 
removal. The impurities include adenovirus proteins- post-translationally modified 
forms, aggregates and incomplete or empty Adenoviral particles. Janssen platform 
active substance specification tests contained the reversed-phase high-performance 
liquid chromatography (RP-HPLC) for viral identity via virus protein fingerprinting and 
the ID-PCR; the impurities (ELISA for the host cell protein and qPCR for the host cell 
DNA); in quantification purposes (VP-qPCR for the virus particle); the safety tests 
were done for endotoxin and bioburden purposes and general tests such as pH, 
polysorbate 80 concentration and appearance.  
1.7 Adenoviral vector platform conclusion  
      To conclude, this chapter has illustrated a model of stabilised Adenoviral vector 
platform from the 10 platforms used for tackling the SARS-COV-2 viruses such as 
Oxford/AstraZeneca (ChAdOx1 nCoV-19) and Janssen (Ad26.Cov2.S). This chapter 
has shown 2 types of AVV platforms, the first was chimpanzee Adenoviral vector 
used by Oxford/AstraZeneca and the second adenovirus type 26 manufactured by 
Janssen. These platforms followed the same method in vaccine manufacturing, 
which was the replication-incompetent vector. The findings among  
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Oxford/AstraZeneca and Janssen platforms showed that there is a matching among 
their content of formulation, which are polysorbate 80 (E433), ethanol 95% and 
sodium chloride. However, the difference is especially for those functioning as a pH 
adjuster, buffering agent and stabiliser/tonicifier. Adenoviral vectors showed to have 
a strong humoral and cellular immunity, its application to the mucosal surface and 
long-term gene expression. In contrast, lack or over attenuation happen with the 
AVV in addition to immune response misdirection. Also, it is expensive for large-
scale manufacturing. The most obvious techniques performed by 
Oxford/AstraZeneca and Janssen for the Adenoviral vector platform, which was 
orthogonal analytical methods to examine the biological activity, safety tests, 
particle/size heterogeneity, infectivity tests and product-related impurities.   
 
Overall, this chapter strengthens the idea that using AVV platform is the best option 
especially for countries that they are suffering from a high-temperature environment 
and needs lower temperature refrigerators for making the vaccine more stable. As a 
result, the Adenoviral vector such as ChAdOx1 nCoV-19 and Ad26.Cov2.S 
formulations can be stored at room temperature 2-8 °C, and there is no need to be 
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CHAPTER 2  




2.1 INTRODUCTION  
        Since the isolation of mRNA in 1961, mRNA platform has been shown to 
induce both of cellular and humoral immune response. mRNA is a safe vector that 
does not interact with the genome (Meselson et al. 1961; Watson et al. 1961). On 
the one hand, mRNA platform is one of the promising alternative vaccines to the 
conventional one. In animal models, mRNA-based therapies elicit a potent immune 
response against infectious diseases. Each mRNA platform has an optimised 
sequence that is encapsulating in a lipid form. However, mRNA vaccine application 
has been restricted because of its instability and the inefficient of its delivery in vivo 
(Pardi et al. 2018). There was a need to advance a COVID-19 vaccine quickly. 
Therefore, all the potential platforms were investigated because of the need for it 
quickly. Even though in the past, mRNA platform shown to be unstable and 
inefficient in its delivery. It ended up being a successful candidate platform and this 
chapter is going to talk about the Pfizer/BioNTech and Moderna mRNA platform, as 
these are examples of the un-stabilised mRNA platform.  
     2.1.1 Introduction to Pfizer/BioNTech COVID-19 vaccine made 
using mRNA platform 
 
The BNT162b2 vaccine developed by the Pfizer/BioNTech pharmaceutical 
companies. BNT162b2 vaccine formulated as a lipid-nucleoside modified mRNA  
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nanoparticle encodes a mutant called P2 mutant spike protein. It induces a blunt 
innate immune system, which results in increasing the antigen expression. Once the 
intramuscular injection made, the vaccine can transfect the optimised mRNA 
platform into the host cells. Through a mixing process of the dissolved LNP and the 









Figure (3): The lipid-nucleoside modified mRNA nanoparticle encodes a mutant 
called P2 mutant spike protein – copied from Krammer (2020 p.520 fig.3).   
 
Additionally, after the intramuscular injection injected, the cells start their uptake of 
LNPs. Then the mRNA vaccine starts releasing its LNP contents into the cytosol that 
can translate the encoded spike protein. Intracellularly, mRNA platform rapidly 
degraded. It ends up with a spike protein-peptide presenting on the cell surface, 
which can trigger a T-cell immune response against the SARS-COV-2 virus spike 
protein (World Health Organisation 2021a).    
 
     2.1.2 Introduction to Moderna COVID-19 vaccine made using 
mRNA platform 
The mRNA-1273 vaccine produced by the Vaccine Research Center at the National 
Institute of Allergy and Infectious Diseases and Moderna pharmaceutical company. 
The mRNA-1273 vaccine is an mRNA-encapsulated LNP that express “the SARS-
COV-2 spike glycoprotein” (European Medicines Agency 2021d; World Health 
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humoral immune response. The encoded antigen spike protein includes Open 
Reading Frame - the 5’ untranslated region (UTR) - and 3’ untranslated region - 






Figure (4): The structure of the encoded antigen spike protein including the 5’ and 3’ 
untranslated regions - copied from European Medicines Agency (2021d p.17 fig.1).  
2.2 Pfizer/BioNTech COVID-19 vaccine  
          The Pfizer/BioNTech COVID-19 vaccine (BNT162b2) prevents the SARS-
COV-2 virus infection through the active immunisation for those aged 16 years and 
older (Medicines & Healthcare products Regulatory Agency 2021b).  
 
     2.2.1 The content, storage conditions and the physical state of 
the formulation 
This part discusses BNT162b2 vaccine content, storage conditions and the physical 
state of the formulation. Table 3 highlights the BNT162b2 vaccine content of the 
formulation, which contains mRNA particle and other excipients with their reported 
concentrations.  
 
Table 3: The content of Pfizer/BioNTech COVID-19 vaccine formulation with their 
reported concentrations (Medicines & Healthcare products Regulatory Agency 
2021b).  
*  The Polyethylene glycol/macrogol (PEG) is part of the ALC-0159 excipient that 
included in this formulation.  
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2 ALC-0159: 2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide.  
3 DSPC: 1,2-Distearoyl-sn-glycero-3-phosphocholine.   
 
Pfizer/BioNTech COVID-19 vaccine (BNT162b2) formulation 
1 dose (0.3 ml) The content of the 
formulation. 
Concentrations per dose. 
mRNA particle BNT162b2 RNA particles. 30 μg particles (World Health 
Organisation 2021f). 
Other excipients 1- ALC-0315 1 0.43 mg (World Health Organisation 
2021f). 
2- ALC-0159 2, * 0.05 mg (World Health Organisation 
2021f). 
3- DSPC 3 0.09 mg (World Health Organisation 
2021f). 
4- Cholesterol. 0.2 mg (World Health Organisation 
2021f). 
5- Potassium chloride. 0.01 mg (World Health Organisation 
2021f). 
6- Potassium dihydrogen 
phosphate. 
0.01 mg (World Health Organisation 
2021f). 
7- Sodium chloride. 0.36 mg (World Health Organisation 
2021f). 
8- Disodium hydrogen 
phosphate dihydrate. 
0.07 mg (World Health Organisation 
2021f). 
9- Sucrose. 6mg (World Health Organisation 
2021f). 
10- Water for injections. Not reported.  
 
The content of Pfizer/BioNTech formulation has some different mRNA particle and 
other excipients from Moderna formulation such as ALC-0315 and ALC-0159, which 
works to provide a functional role for the lipid nanoparticle; potassium dihydrogen 
phosphate, sodium chloride, disodium hydrogen phosphate dihydrate and potassium 
chloride acting as buffer component (European Medicines Agency 2021a). In 
contrast to Pfizer/BioNTech formulation, however, Moderna formulation used Lipid 
SM-102 and PEG2000-DMG as a carrier and protectants for the mRNA platform; 
Tromethamol and Tromethamol hydrochloride were used as a neutralising for the 
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The knowledge of BNT162b2 vaccine storage conditions and the physical state is 
crucial for a better understanding of mRNA stability. There is a need for BNT162b2 
vaccine to be stored for up to 6 months at ultra-low freezing temperature. The 
BNT162b2 vaccine storage temperature is –70 °C ±10 °C, which needs to control 
the storage with a very low-temperature by using dry ice temperature-controlled 
thermal shippers throughout transportation processes (World Health Organisation 
2021a). Also, it should not re-frozen while the vaccine thaws. During the storage 
process, the packaging uses to minimise the formulation from ultraviolet light and 
sunlight exposure. The colour of the BNT162b2 vaccine product is off-white frozen 
dispersion (World Health Organisation 2021f). Accordingly, it seems BNT162b2 
vaccine needs some improvement for the formulation storage within the acceptable 
degree of temperatures, which makes it available during the shipping process 
without any obstacles. 
2.3 Moderna COVID-19 vaccine  
          The Moderna COVID-19 vaccine (mRNA-1273) prevents the SARS-COV-2 
virus through the “active immunisation” of those aged 18 years old and older (World 
Health Organisation 2021h).  
 
     2.3.1 The content, storage conditions and the physical state of 
the formulation 
        
This part discusses mRNA-1273 vaccine content, storage conditions and the 
physical state of the formulation. Table 4 highlights the mRNA-1273 vaccine content 
of the formulation which contains a viral particle and other excipients with their 
reported concentrations. 
 
Table 4: The content of Moderna COVID-19 vaccine formulation with their reported 
concentrations (Medicines & Healthcare products Regulatory Agency 2021c).  
*The Polyethylene glycol/macrogol (PEG) is part of the PEG2000-DMG 
excipient that included in below formulation.   
1 DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine.   
 17 
 
CHAPTER 2                                   The model of un-stabilised COVID-19 vaccine: mRNA platform  
 
2 PEG2000-DMG: 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000.  
Moderna COVID-19 vaccine (mRNA-1273) formulation 
1 dose (0.5 ml) The content of the 
formulation. 
Concentrations in the final 
product (mg/ml). 
mRNA particle mRNA-1273 particles. 0.20 (World Health Organisation 
2021h).  
Other excipients 1- Lipid SM-102.  2.15 (World Health Organisation 
2021h).  
2- Cholesterol.  0.94 (World Health Organisation 
2021h). 
3- DSPC1 0.55 (World Health Organisation 
2021h). 
4- PEG2000-DMG*,2 0.23 (World Health Organisation 
2021h). 




2.35 (World Health Organisation 
2021h). 
7- Acetic acid.  0.085 (World Health 
Organisation 2021h). 
8- Sodium acetate trihydrate.  0.237 (World Health 
Organisation 2021h). 
9- Sucrose.  87 (World Health Organisation 
2021h). 
10- Water for injections.  Not reported.  
 
The content of Moderna formulation has some same mRNA particle and other 
excipients from Pfizer/BioNTech platform such as DSPC, cholesterol, sucrose and 
water for injection (World Health Organisation 2021f; World Health Organisation 
2021h).  
 
A better understanding of mRNA-1273 storage conditions and physical state is 
crucial for more knowledge about mRNA stability. mRNA-1273 vaccine shelf-life 
storage is -20°C ±5°C. According to the demonstrated data, when the mRNA 
vaccine stored at -70°C, there was no change in the biophysical state of the LNP 
and the mRNA purity. However, at 25°C, 5°C and -20°C, the chemical degradation of 
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vaccine was -20°C (European Medicines Agency 2021d). The colour of the vaccine 
product is white to off-white, and it is a frozen dispersion formulation (European 
Medicines Agency 2021d; National Pharmacy Association 2021).  
 
2.4 The strengths of the mRNA platform 
 
         In vaccine development, each platform has strengths and weaknesses. This 
part intends to discuss the mRNA platform strengths. In terms of the mRNA effects 
on the immune system, it can induce humoral and cellular immunity against the 
introduced antigens. In regards to cytosolic translocation, it can enhance the direct 
delivery of the antigen expression into the cytosol (Haque and Pant 2020). 
Regarding its manufacturing process, mRNA platform produced with a rapid capacity 
(Haque and Pant 2020) and completely produced in vitro (Krammer 2020). In terms 
of its lipid moieties, mRNA platform designed for self-adjuvating purposes. Further, 
with its genetic expression, mRNA platform does not interact with the genome. For 
the causation of the adverse effects, it is less likely to cause allergens (Haque and 
Pant 2020) as it is readily adaptable (Crommelin et al. 2021b).   
 
2.5 The weaknesses of the mRNA platform  
 
         mRNA platform has six key weaknesses in vaccine development. Regarding 
immunity, mRNA has a limitation to its immunogenicity, which encodes few 
fragments rather than the whole virus. The immunostimulation weaknesses happen 
due to the lack of endosomal RNA receptors interact with the mRNA platform. 
Regarding its storage, mRNA platform needs to be storing at a cooler temperature 
(Haque and Pant 2020). According to Krammer (2020) clarification, mRNA is a new 
technology and the needs for frozen storage might encounter unclear issues in the 
long term regarding its storage stability. In mRNA manufacturing, there are some 
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via injection, hence it is less likely to induce a strong mucosal immunity (Krammer 
2020).   
 
2.6 Characterisation techniques for the Pfizer/BioNTech 
and Moderna platform  
     
        An experimental investigation was conducted by Pfizer/BioNTech and Moderna 
to characterise the BNT162b2 and mRNA-1273 platforms. In terms of the BNT162b2 
platform, analytical characterisation methods were used separately such as Liquid 
Chromatography–Ultraviolet/Mass Spectrometry (LC-UV/MS) and RP-HPLC to 
analyse the physico-chemical characteristics of 3’ poly(A) tail and the 5’ cap 
structure; orthogonal method, oligonucleotide mapping and Next Generation 
Sequencing (NGS) technology were applied to confirm the primary structure. 
Accordingly, the RNA sequence results were confirmed the quality attributes and the 
expected sequence including the full-length nucleotide sequence after using these 
techniques. Further specifications were performed to test the active substance 
colouration and clarity using the appearance test; UV spectroscopy for the RNA 
concentration (content); Capillary Gel Electrophoresis to characterise the RNA 
integrity; ddPCR to characterise the Poly(A) Tail; RT-PCR for the encoded RNA 
sequence identification; qPCR to look at the Residual DNA Template; Immunoblot 
for the dsRNA; bacterial endotoxin and bioburden (European Medicines Agency 
2021a).   
 
Regarding the mRNA-1273 platform, specification tests used to test the active 
substances such as RT- Sanger sequencing for the platform identification; UV 
spectroscopy to characterise the total RNA concentration (content); RP-HPLC for the 
vaccine purity, impurities and the product percentage of the poly A tailed RNA; qPCR 
to look at the Residual DNA Template; RP-UPLC to quantify the product percentage 
of the 5’ Capped; bacterial endotoxin and bioburden (European Medicines Agency 
2021d). The above specification tests for the BNT162b2 and mRNA-1273 platform 
gave acceptable results for their active substances to be authorised.   
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2.7 Problems of the mRNA platform including its instability 
 
        In the pharmaceutical biotechnology industry, the instability sources of mRNA-
based therapies may hinder its potential work. An example of unstable mRNA 
platform is the Pfizer/BioNTech and Moderna vaccine (Tinari 2021). This part 
clarifies some sources that affect mRNA stability (Pardi et al. 2018). mRNA platform 
is susceptible to both chemical and enzymatic pathways of degradation (Geall et al. 
2013). It is highly sensitive to degradation because of its single-stranded structure, 
divalent ions, and RNases of the buffer formulation (Brawerman 1974; Burgess 
2012; Muralidhara et al. 2016). The other major instability source of the mRNA 
platform is the unstable factors in the 3′ untranslated region (UTR) (Xu et al. 2020).  
 
Accordingly, a better understanding of mRNA properties and the causes of its 
instability will help us select more appropriate technologies for a stabilised mRNA 
platform to be shipped with ambient temperatures (Crommelin et al. 2021a). mRNA 
platform has got several potentials as it is highly immunogenic, but its instability 
makes it challenging. The pharmaceutical industry is interested in identifying 
potential ways of stabilising the mRNA vaccine. Therefore, the next section will 
discuss the potential application of whether the human serum albumin could stabilise 
mRNA platform.    
 
2.8 The application of the human serum albumin as a 
stabiliser for mRNA platform 
 
    2.8.1 Introduction 
         Knowledge of the human serum albumin (HSA) properties and characteristics 
is crucial to understand its approach in stabilising biopharmaceuticals and the mRNA 
platform in particular. Human serum albumin is a very stable protein and is 
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(Sleep et al. 2013). Structurally it is a multi-domain monomeric protein with a major 
role in the transport of structurally diverse compounds and in maintaining the oncotic 
pressure among the body compartments (Fanali et al. 2012). Its structural flexibility 
determines its multifunctional role in the interaction with endogenous and exogenous 
compounds. It is interacting with the intracellular and extracellular viral components 
as it is highly recommended as a deliverer, therapeutic material and stabiliser for 
drugs (Mani Mishra et al. 2020).   
     2.8.2 The structure-function relationship of human serum 
albumin  
 
Human serum albumin is a 585 amino acids single polypeptide chain with molecular 
weight of 66.5 kDa. The HSA polypeptide chain has no carbohydrate moiety with a 
shortage of methionine and tryptophan residues, and a high amount of charged 
residues including aspartic acid, arginine, lysine and glutamic acid (Theodore Peters 
1995). The HSA shape in the solution is different (Nicholson et al. 2000) as it is 
flexible molecule and its variations depend on the binding with ligands and the 
environmental conditions (Peters Jr 1995). Human serum albumin is a versatile 
carrier protein for advancing the pharmacokinetic profile and drug targeting of 
protein-based drugs and peptides (Kratz 2008). According to Larsen et al. (2016), 
human serum albumin has multiple engagement cellular receptors and ligand 
binding sites, which interact with a receptor called neonatal Fc. These properties 
make HSA more attractive candidate macromolecules for drug delivery targeting via 
covalent conjugation bond attachment. As with HSA solubility, it is a water-soluble 
protein due to its high overall negative charge at neutral pH. Figure 5 shows the 
classical 3-D heart-shaped structure of the HSA obtained by using X-ray 


















Figure 5: The tertiary crystal structure of the human serum albumin with its three 
domains (PDB 1e7e). Domain one (IA; purple and IB; red); domain two (IIA; green 
and IIB; orange) and domain three (IIIA; blue and IIIB; violet). In domain one (IA) 
highlights the existence of cysteine 34 residues that have disulfide bridges showing 
yellow sphere sticks – Copied from Larsen et al. (2016 p.2 fig.1).  
 
Cysteine at position 34 (cys34) contributes together with the Methionines, to the anti-
oxidising properties of the HSA, which contains a single free thiol group (-SH) for 
covalent attachment with drugs and antioxidant properties. The single free cysteine 
residues make HSA also attractive for drug delivery (Quinlan et al. 2005). 
Accordingly, the understanding of plasma-derived human serum albumin mechanism 
for stabilising transfer RNA (tRNA), can be a key tool to apply in developing stable 
mRNA platform.   
2.9 The interaction of human serum albumin for stabilising 
tRNA with a potential for mRNA platform 
      The serum-derived human albumin is a major target for nucleobases, 
nucleotides, RNA and DNA binding (Malonga et al. 2006a). According to Malonga et 
al. (2006b) paper, in aqueous solution, it was tested the interaction of HSA with the 
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genetic information and proteins (Giegé et al. 1998). To determine the tRNA-HSA 
complexes, association constant, the changes in the HSA secondary structure and 
the mode of HSA binding; FTIR spectroscopic and Affinity capillary electrophoresis 
were used. The result showed 2 types of the tRNA-HSA complexes bounded. The 
first type, HSA main binding sites on tRNA are PO2 backbone group and G-C bases. 
The second type, the HSA parts such as NH2 groups, C–N and C=O are the main 
sites of binding with tRNA (Malonga et al. 2006b). Accordingly, the complex binding 
among tRNA-HSA showed the tRNA stabilised with no change in the conformation 
and the secondary structure of the HSA protein remained stable, as well (Malonga et 
al. 2006b).   
 
mRNA acts as a molecule with an abundance of information between translating 
ribosomes and the DNA (Del Campo et al. 2015). Also, the mRNA consists of G 
(guanine) -C (cytosine) bases (Hames and Hooper 2011). As shown in Van Hoecke 
and Roose (2019) article, mRNA has a negative charge. It is obvious from the 
interaction of HSA with tRNA that HSA has positive charges came from NH2 groups, 
C–N and C=O. Previous reviews have only focused on tRNA to address its stability 
with HSA instead of the mRNA. In the case of mRNA, it is possible for the HSA to 
stabilise mRNA platform as the same as did with the tRNA from the positive-negative 
interaction.   
 
2.10 mRNA platform conclusion 
 
To sum up, this chapter has shown a model of un-stabilised mRNA platform from the 
10 platforms used for tackling the SARS-COV-2 virus such as Pfizer/BioNTech 
(BNT162b2) and Moderna (mRNA-1273). This chapter has illustrated the 
Pfizer/BioNTech and Moderna platforms, which are lipid-nucleoside modified mRNA 
nanoparticle encodes the SARS-COV-2 spike glycoprotein. These platforms followed 
the same method in vaccine manufacturing, by encapsulating the encoded mRNA 
platform in a lipid nanoparticle. This chapter has found that Pfizer/BioNTech and 
Moderna platforms showed a similarity among their content of  
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formulation, which are DSPC, cholesterol, sucrose, and water. On the other hand, 
the disparities are for those functioning as a lipid nanoparticle, buffer component, 
protectants, and carrier for the mRNA and for maintaining the pH at low values. 
mRNA illustrated to induce a strong humoral and cellular immunity, its direct delivery 
to the cytosol and rapid manufacturing capacity process. Also, it is designed to be 
self-adjuvating with less interaction with genome. In contrast, the main weakness is 
needs to be storing at a lower frozen temperature, which affect on the long-term 
storage stability.  
 
The most obvious techniques performed by Pfizer/BioNTech and Moderna for the 
mRNA platform, which were RP-HPLC for the vaccine purity and to analyse 
the physico-chemical characteristics of 3’ poly(A) tail and the 5’ cap structure. Also, 
the UV spectroscopy were used to characterise the total RNA concentration 
(content). Moreover, mRNA have sources of instability, which are susceptible to both 
chemical and enzymatic pathways of degradation because of its single-stranded 
structure, divalent ions, and RNases of the buffer formulation. Additionally, it is 
unstable factors in the 3′ untranslated region. Overall, this chapter strengthens the 
idea that mRNA is unstable platform and needs -70°C temperature refrigerators for 
making the vaccine more stable for high-temperature environment countries. As a 
result, this chapter suggested the potential application of the serum-derived human 
albumin as a stabiliser for the mRNA platform. It was shown the HSA stabilise the 
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CHAPTER 3  
 
Concluding Remarks and Perspectives 
 
 Our short review has considered a model of stabilised (AVV) and un-stabilised 
(mRNA) platforms from 10 platforms that used for tackling SARS-COV-2 virus. 
Oxford/AstraZeneca and Janssen are examples on AVV platform, however, 
Pfizer/BioNTech and Moderna are examples on mRNA platforms. It has discussed 
AVV including the chimpanzee Adenoviral and adenovirus type 26 are more 
stabilised platforms than the mRNA nanoparticle platform. The findings showed that 
AVV and mRNA platforms have their own content of the formulation even for the 
same platform with a few similarities. Also, both of AVV and mRNA platforms 
illustrated to induce a strong humoral and cellular immunity. Nonetheless, mRNA 
was un-stabilised form and needs to be storing at a lower frozen temperature, which 
affect on the long-term storage stability. This due to its instability sources, which are 
susceptible to both chemical and enzymatic pathways of degradation; it’s unstable 
factors in the 3′ untranslated region; it’s single-stranded structure, divalent ions, and 
RNases of the buffer formulation.  
 
The most obvious techniques performed by Oxford/AstraZeneca and Janssen for the 
Adenoviral vector platform, which was orthogonal analytical methods to examine the 
biological activity, safety tests, particle/size heterogeneity, infectivity tests and 
product-related impurities. On the other hand, Pfizer/BioNTech and Moderna 
examined the mRNA platform through the RP-HPLC for the vaccine purity and to 
analyse the physico-chemical characteristics of 3’ poly(A) tail and the 5’ cap 
structure. Also, the UV spectroscopy were used to characterise the total RNA 
concentration (content). Overall, this research paper has strengthened the idea that 
the AVV is a stabilise form of Covid-19 vaccine, which can be stored at 2-8 °C and 
there is no need for further manipulations. However, mRNA is un-stabilised form of  
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Covid-19 vaccine, which can be stored at -70°C and this storage making the vaccine 
less stable especially for high-temperature environment countries. The potential 
application of the serum-derived human albumin (HSA) as a stabiliser for the mRNA 
platform is clearly worth exploring in more detail not just for stabilising the mRNA 
platform vaccines but also the Adenovirus based ones. Further research is indicated 
including the possible effects of non-specific interactions with antibodies generated 
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Background: Hydrodynamic methods such as analytical ultracentrifugation, 
dynamic light scattering, SDS-PAGE, viscosity analysis, dialysis tubing and UV 
spectroscopy were employed. These methods were to investigate the 
heterogeneity/homogeneity, molecular weights, purity, the concentration 
measurements, solution conformations and intrinsic viscosity of IgG A 33 hFab’ and 
human serum albumin (HSA). Both macromolecules relevant in cancer and 
biopharmaceutical therapies. We also investigate the properties of mixtures of the 
two, probing for a possible interaction, which will help in developing formulations of 
cancer and biopharmaceutical therapeutics in the future.  
 
Methods: The dialysis experiment was performed to produce pure samples of HSA 
and IgG A33hFab’ macromolecules and measuring the concentration via UV 
spectroscopy. Determination of the molecular weight was applied by using SDS-
PAGE and sedimentation equilibrium (SE) for both macromolecules. To analyse the 
HSA and IgG A33 hFab’ purity and the presence of possible dimers and aggregates, 
the SV method was performed. Also, the SV was utilised to obtain more information 
about the possible interaction between the IgG A33 hFab’ and human serum 
albumin. The dynamic light scattering method was utilised to further evaluate the 
heterogeneity of the IgG A33 hFab’ macromolecule. Viscosity measurements were 
applied to determine IgG A33 hFab’ and human serum albumin macromolecules 
shape with their intrinsic viscosities, using Ostwald (U-tube) capillary viscometer.  
 
Results: DLS results reinforced by sedimentation velocity (single peak) showed that 
IgG A33 hFab’ is homogenous and free of aggregated particles. Its molecular weight 
is ~ 48- 50 kDa and monomeric state using the SDS-PAGE and SE methods. HSA 
molecular weight is also shown to be homogenous from sedimentation velocity with 
a molecular weight of 70.6 kDa using the absorbance optical system in SE method. 
A single sedimentation peak was also seen in mixtures of HSA with IgG A33 hFab’. 
This could either be due to an interaction or due to the Johnston-Ogston effect. 
Using ELLIPS (molecular shape) both IgG A33 hFab’ and HSA are globular with very 
similar axial ratios. These results will advance the knowledge in biotherapeutics for 
an effective formulation in manufacturing process.  
 
                                                                                 II 
 
 
Keywords: Human serum albumin, IgG A33 hFab’, cancer immunotherapy and 







°C                                            Celsius 
DLS                                         Dynamic light scattering  
D20,w                                     
 
HSA                                         Human serum albumin                                        
IgG A33 hFab’                          
kDa                                          KiloDalton  
M.wt                                         Molecular weight (kDa or g.mol-1)  
Mw                                      Weight average molecular weight 
Mw,app     Apparent weight average molecular weight   
hr                                             Relative viscosity 
[h]                                            Intrinsic viscosity (ml/g) 
ηred                                            Reduced viscosity 
PBS                                         Phosphate – buffered saline  
SV                                           Sedimentation velocity  
SE                                           Sedimentation equilibrium  
SDS-PAGE                           
s20,w                                                         
 
UV-spectrophotometer            Ultraviolet spectrophotometer             






Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis 
 
Antibody fragment of the murine monoclonal antibody (MAb)                 
 
Sedimentation coefficient normalised to standard solvent 
conditions: density and the viscosity of water at 20.0°C. (Unit: S) 
The diffusion coefficients corrected for the viscosity and density at 







1. Introduction   
 
         A humanised antibody recognised by murine monoclonal antibody (MAb) fab 
fragment, is attracting interest due to its application in cancer immunotherapies. Its 
potential application is using for the treatment or diagnosis of colorectal metastases 
and tumours with patients in the Western world. The humanisation techniques of the 
chimeric antibodies showed a lower immune response -immunogenicity- in 
comparison with the murine monoclonal antibody (King et al. 2001). However, in 
cancer therapies, generally, the half-life of the fab fragment ≈ 28 min, through its 
conjugation with tumours due to the lower molecular weight (size) (Xenaki et al. 
2017). This limitation may arise with the IgG A33 hFab’ macromolecule, which ends 
up with a reduction of the IgG A33 hFab’ macromolecule usefulness and efficacy as 
a therapeutic agent. Figure 1-A showing the full antibody predicted with the small 





Figure 1: A surface shape of (A) full IgG2a/k antibody prediction (PDBid:1IGT) and 





IgG2a/k antibody with its fab fragment created using “The Pymol Molecular Graphics 
System, Version 2.5.0 Schrödinger, LLC”.  
 
The extension of biotherapeutics half-life plays a major role in improving patient’s life 
by reducing the burdens on them. Also, the extension of half-life recognised by the 
biopharmaceutical industries with around 15% of the biotherapeutics was amended 
for this purpose (Walsh 2014). To overcome the half-life issue of the fab fragment in 
general and the IgG A33 hFab’ particularly, however, human serum albumin (HSA) 
has ≈19-21 days half-life in the human blood (see figure 2) (Sand et al. 2015). 
Further, HSA minimising the drug-induced cytotoxicity, enhancing the tumour 
specificity and maintains the active agent of therapeutics concentration such as 




Figure 2: A tertiary structure of human serum albumin, represented as spheres in 
shape (PDBid: 4LB2). The HSA structure was created using “The Pymol Molecular 
Graphics System, Version 2.5.0 Schrödinger, LLC”.   
 
Since the shortage of IgG A33 hFab’ macromolecule half-life is the main concern in 
the biotherapeutics manufacturing development. The HSA can be applied to extend 
the IgG A33 hFab’ half-life, as it is not yet known whether HSA can interact with IgG 





half-life can be extended or not. This experimental study aims to characterise the 
solution behaviour of IgG A33 hFab’ and human serum albumin macromolecules 
using several hydrodynamic techniques, and to investigate a possible interaction 
between them. The objectives of this experimental study are to, first, produce pure 
samples of human serum albumin and IgG A33 hFab’ macromolecules using a 
dialysis-tubing experiment, with concentration subsequently measured by UV 
spectrophotometer. Second, to determine the molecular weight of the IgG A33 hFab’ 
using SDS-PAGE and sedimentation equilibrium (SE) for both macromolecules. 
Third, to assess the IgG A33 hFab’ and the human serum albumin macromolecules 
purity and the presence of possible dimers and aggregates using sedimentation 
velocity (SV) of the analytical ultracentrifugation. This is because the interaction 
medium needs a pure sample of both HSA and IgG A33 hFab’ and free of the 
aggregated particles. Additionally, to investigate a possible interaction among the 
IgG A33 hFab’ and human serum albumin through SV, as well. Then, to further 
evaluate the heterogeneity of the IgG A33 hFab’ by applying the dynamic light 
scattering method. Finally, viscosity measurements will apply to evaluate the 
molecular shape in solution of IgG A33 hFab’ and human serum albumin 
macromolecules with their intrinsic viscosities, for expanding the knowledge of 
























2. Materials and methods   
2.1. Materials     
 
              Stock solutions were prepared of IgG A33 hFab’ (tWB E-017578, UCB 
Celltech, United Kingdom) and human serum albumin (Albumedix, United Kingdom), 
pH 7.0, in phosphate-buffered saline (PBS: NaCl, KH2PO4 and Na2HPO4.12H2O), 
with an adjusted ionic strength (I) equal to 0.1 M. The PBS buffer was used as an 
aqueous solvent and stored at 2–8 °C. The 2x Laemmli sample buffer was obtained 
from BIO-RAD Laboratories (USA). Precision Plus ProteinTM Standards, Dual colour 
Standards from BIO-RAD (USA) as a ladder for determining the molecular weight 
through the gel. The 10x Tris/Glycine/SDS buffer from BIO-RAD (USA). 2-
Mercaptoethanol (≥ 99.0%, M6250, Lot # STBJ9454) was provided by Sigma-
Aldrich® (USA). InstantBlue® Coomassie Protein Stain (ISB1L) lot GR3392748-1. 
BioDesignDialysis TubingTM (D004) was supplied by THERMOFISHER SCIENTIFIC, 
BioDesign Inc. (New York, USA). Disposable cuvettes were from PLASTIBRAND® 
(Germany). Polystyrol/Polystyrene cuvettes with 10 × 10 × 45 mm (REF.67.74. 1) 
were from SARSTEDT AG& Co. (Germany). The GraphPad Prism software program 
was used to create plots in the Results and Discussion sections of this report.  
 
2.2. Methods  
 
          2.2.1 Dialysis  
 
            This procedure used BioDesignDialysis TubingTM (D004), which had 21.3 mm 
wet diameter and 3.57 ml/cm volume (14000 MWCO). The endings were tied tightly 
to avoid any leakage from inside or outside the tubing dialysis with the PBS buffer 
solution. The IgG A33 hFab’ and HSA macromolecules were pipetted and dialysed 
against the PBS buffer in separate experiments for both of them. Afterwards, it was 
tied again from the other end, leaving a small air bubble inside the tubing bag. Later, 
the BioDesignDialysis TubingTM was stored in the refrigerator at 4 °C and then the 
final dialysed concentration measured. This procedure was followed for both the IgG 






          2.2.2 UV spectrophotometer 
 
             The concentration measurement procedure was performed to verify the 
dialysed samples of IgG A33 hFab’ and HSA macromolecules using a UV 
spectrophotometer. They were prepared and diluted in a PBS buffer in a ratio of 1:5 
and 1:2, respectively, Then, the UNICAM Helios β instrument and 2 disposable 
cuvettes – 1 cm in length – were employed to measure these samples with PBS 
buffer as a reference. Five measurements were run individually for obtaining the 
absorbance with a fixed wavelength at ε280 = 1370 ml.g-1.cm-1 (IgG A33 hFab’) and 
538 ml.g-1.cm-1 (HSA). Afterwards, the c (mg/ml) was calculated using the Beer-
Lambert Law equation as follow:    
 
𝚨 = 	ℇ𝟐𝟖𝟎	 × 	𝒃	 × 	𝑪	                                         (1) 
 
where A is the absorbance of the IgG A33 hFab’ and HSA macromolecules at 280 
and b is the path length of the cuvette in cm (Swinehart 1962). 
 
        2.2.3 Dynamic Light Scattering   
 
          Dynamic light scattering (DLS) measurements were done using a Malvern 
(ZETASIZER) Nano Series - Nano- ZS instrument. 1.0 mg/ml and 0.5 mg/ml 
solutions of the IgG A33 hFab’ macromolecule were placed in DTS0012 - Disposable 
polystyrol/polystyrene sizing cuvettes (Malvern Instruments Ltd., UK). The IgG A33 
hFab’ sample was examined at (20.0 ± 0.1) °C through using dual angles which were 
173° (Backscatter) and 13° (Forwardscatter) for the different concentrations, 
collected for 1 run of 120 seconds period per concertation. After that, the IgG A33 
hFab’ sample and the PBS buffer were filtrated from probable dust particles, airborne 
and large aggregates. Therefore, the sensitivity of the DLS method was considered 
by handling dust removal, to remove any dust particles and airborne for the light 
scattering detector chamber, Eppendorf tubes and the cuvettes. We used Malvern’s 
Zetasizer commercially available software to measure the hydrodynamic sizes (rH) in 
nm or cm of the IgG A33 hFab’ macromolecule and the size distribution (expressed 






The translational hydrodynamic or “Stokes” radius was evaluated by the software 
from the translational diffusion coefficient D20,w calculated using Stokes equation as 
shown below (see, for example, Harding (1994)):   
 
                                      rH = 𝐤𝐁	×	𝐓𝟔	×	𝛑	×	𝛈𝟐𝟎,𝐰	×	𝐃𝟐𝟎,𝐰                                                (2)  
 
where, kB is the Boltzmann constant which is equal (1.38062x 10-16 !"#
$
), T is the 
absolute temperature in Kelvin and η20,w is the water viscosity at 20.0 °C.   
 
        2.2.4 Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis 
 
          A 1 mg/ml aliquot was prepared from the IgG A33 hFab’ stock solution to 
estimate its molecular weight using Sodium Dodecyl Sulphate – Polyacrylamide Gel 
Electrophoresis (SDS-PAGE). Briefly, this method followed using Mini-PROTEAN® 
TGXTM Precast Gels were supplied from BIO-RAD (USA). The comb and tape 
(green) were removed to make it ready for running by Mini-PROTEAN® Tetra 
Vertical Electrophoresis Cell from BIO-RAD (USA). Heating was applied for IgG A33 
hFab’ sample for around 5 min at ≃ 100 °C. Afterwards, 2x Laemmli sample buffer 
(purple) was prepared with 2-mercaptoethanol for a total volume= 100 μl. Then, 10x 
Tris/Glycine/SDS buffer poured inside and outside the chambers in Mini-PROTEAN® 
Tetra Vertical Electrophoresis Cell, with a 9:1 concentration ratio of the RO/milli-Q 
water sample, which used as a running buffer, as well. It was assured that the wells 
are rinsed with Tris/Glycine/SDS buffer before start running the gel. The prepared 
samples with their gradient concentrations were loaded in wells starting with 4 μl of 
the Dual colour Standards. Through running Precast Gels, the voltage was set at 80 
volts for 15 min, later, it was increased to 180 volts. At the end, the cassette gel was 
opened and immersed in InstantBlue® Coomassie protein stain with a slow shaking 
overnight using 2D Rocker from Flowgen Biosciences, for getting a clear and visible 







      2.2.5 Analytical Ultracentrifugation- Sedimentation Equilibrium analysis 
          
          Analytical ultracentrifugation has 2 basic methods, which are the 
sedimentation equilibrium (SE) method and the sedimentation velocity (SV) method 
(Ralston 1993). The measurements were taken using a Beckman Optima XL-I 
Analytical Ultracentrifuge (Beckman Coulter, Brea, CA, USA) for both SE and SV 
methods. Both Rayleigh interference and UV-absorbance optical systems were 
used. The SV method was used to assess the homogeneity and measure the 
sedimentation coefficient distribution. The SE method, was utilised to measure the 
IgG A33 hFab’ and HSA macromolecules molecular weight (Schuck et al. 2014). The 
centrifuge cells used in this method were constructed from sapphire windows which 
were sealed in an aluminium cell housing, aluminium epoxy resin centrepiece, 
double sectored. Additionally, 140 μl of IgG A33 hFab’ and 100 μl of HSA with PBS 
buffer (as a reference) was taken and injected into the centrifuge-housing cells 
individually. After that, the centrifuge cells were loaded and balanced in a 4-hole 
rotator, and run at the appropriate speed at a temperature equal to (20.0 ± 0.1) °C. 
Subsequently, the SEDFIT-MSTARv1 software (Schuck et al. 2014) was used to 
analyse the interference and absorbance data, for calculating the apparent weight 
average molecular weight Mw,app.   
 
      2.2.6 Analytical Ultracentrifugation- Sedimentation Velocity analysis 
         
        In this method, the SV was applied to assess the IgG A33 hFab’ purity and the 
presence of dimers and aggregates, with UV-absorption optics and Rayleigh 
interference (Harding 2005). The IgG A33 hFab’ samples were diluted from their 
stock solution starting from 1.20 mg/ml to 0.02 mg/ml. The centrifuge cells employed 
in this experiment were created from aluminium epoxy resin centrepiece, double 
sectored, sapphire windows which were sealed in an aluminium cell housing. 
Therefore, 400 μl of both IgG A33 hFab’ and PBS buffer as a reference was taken 
and injected in the centrifuge cell housing individually. Then, the centrifuge cells 
were loaded and balanced in a 4-hole rotor. The Beckman Optima XL-I Analytical 
Ultracentrifuge instrument was calibrated at a temperature equal to (20.0±0.1) °C, 





analyse the absorbance and interference data, to calculate the sedimentation 
coefficient values and distributions for each concentration.  
 
SV was also utilised to determine the interaction between human serum albumin and 
IgG A33 hFab’ macromolecules. The method was followed similarly as with IgG A33 
hFab’ SV method. However, in the SV method for investigating their interaction, the 
concentrations of the relative proportions for both macromolecules were (1:1), (1) for 
the IgG A33 hFab’ only and (1) for the HSA only. 
 
      2.2.7 Ostwald (U-tube) capillary viscometer  
 
         IgG A33 hFab’ and HSA macromolecules were tested to assess their molecular 
shape and the intrinsic viscosity, using an automated Ostwald (U-tube) capillary 
viscometer (Schott Geräte, Hofheim, Germany). The temperature in the water bath 
was controlled at (20.0°C ±0.01). In addition, at a fixed concentration of IgG A33 
hFab’ and series concentrations of the HSA macromolecules, five flow times (t0) 
were measured to calculate the PBS buffer; also, the IgG A33 hFab’ and HSA 
samples flow times (t) calculated with their average values for obtaining more 
reliable and precise results. The densities of the PBS buffer, IgG A33 hFab’ and HSA 
samples were calculated using DMA 5000 M, Density meter, Anton Paar (Graz, 
Austria). The relative viscosities were obtained using the following equation (see, 
e.g., Gillis et al. (2014); (Harding 1997)):    
 
𝜼𝐫 = ( 𝒕
𝒕𝝄	
) 	× 	( 𝝆
𝝆𝝄
)	                                          (3.1) 
where, hr is the relative viscosity of the IgG A33 hFab’ and HSA sample, 𝑡 is the IgG 
A33 hFab’ and HSA solution flow time, 𝑡𝜊 is the PBS buffer flow time, 𝜌 is the density 
of the IgG A33 hFab’ and HSA solutions and 𝜌𝜊 is the density of the PBS buffer.   
Afterwards, the intrinsic viscosity was calculated using the Solomon-Ciuta equation 
in accordance with the relative viscosity in equation (3.1) (Harding 1997):   
[𝜼] ≅ 	1𝟐((𝜼𝒓5𝟏)5𝟐	𝒍𝒏(𝜼𝒓))
𝑪





where, [h] is the IgG A33 fab’ and HSA intrinsic viscosity and C is the concentration 
in g/ml. Furthermore, [h] from equation (3.2) was used to calculate the shape factor 
of the IgG A33 hFab’ using the following equation (Harding 1997):  
𝝊 = 	 [𝜼]
𝒗𝒔
                                                       (3.3) 
where, n is the viscosity increment, ns is the “swollen” or “hydrated” specific volume 
for the IgG A33 or hFab’ samples, i.e. swollen volume per unit anhydrous mass. For 
HSA, the intrinsic viscosity was evaluated using equation (3.2) and the following 
equations (see Harding (1997); (Jiwani et al. 2020)):  
 	𝛈𝐫𝐞𝐝 = [𝜼]. (𝟏 + 𝑲𝑯[	𝜼]𝒄)			                                (3.4) 
				(𝒍𝒏	𝜼𝒓)
𝒄
= [𝜼](𝟏 − 𝑲𝑲[	𝜼]𝒄)		                                   (3.5) 


















3. Results and Discussion 
 
       3.1 Producing a pure sample of IgG A33 hFab' and HSA through dialysis 
and with their concentration measurements 
 
             Human serum albumin and IgG A33 hFab’ macromolecules were dialysed 
before measuring their concentrations. The dialysis experiment aimed to purify the 
contents of the dialysis tubing from the impurities and salts such as NaCl. The 
results of pre-and post-dialysis were the concentration for the IgG A33 hFab’ 
decreased but human serum albumin increased. Table 1 shows the concentrations 
of HSA and IgG A33 hFab’ macromolecules were taken after running the dialysis 
experiment. 
 
Table 1: The average absorbance and concentration of IgG A33 hFab’ and HSA with 





Absorbance (A) C (mg/ml) 
Measurement (1) IgG A33 hFab’ 0.352 1.285 
Measurement (2) IgG A33 hFab’ 0.353 1.288 
Measurement (3) IgG A33 hFab’ 0.355 1.296 
Measurement (4) IgG A33 hFab’ 0.356 1.299 
Measurement (5) IgG A33 hFab’ 0.357 1.303 
Average - 0.355 (± 0.002) 1.294 (± 0.008) 
Measurement (1) HSA  0.839 3.119 
Measurement (2) HSA 0.838 3.115 
Measurement (3) HSA 0.836 3.108 
Measurement (4) HSA 0.835 3.104 
Measurement (5) HSA 0.835 3.104 
Average - 0.8366 (± 0.0018) 3.110 (± 0.007) 
 
Table 1 illustrates the absorbance values obtained from the UV spectrophotometer 
using equation (1) (see section 2.2.2). As shown in Table 1, the concentration of IgG 





= (3.11 ± 0.01) mg.ml-1. The linearity relation between absorbance and concentration 
values was confirmed by Gobrecht et al. (2015).  
 





Figure 3: Dynamic light scattering method of IgG A33 hFab’ macromolecule. Each 
one of the above diagrams; A, B, C and D represents multiple measurements of the 
volume distribution (%) as a function of hydrodynamic size (r.nm) and the diffusion 
coefficient, D20,w (%²' ) for dual angles at 20.0 ° C. The scattering angles for plots A 
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and C were measured using 13° forwardscatter. In contrast, the scattering angles for 
plots B and D were measured using 173° backscatter.    
 
The dynamic light scattering experiment represents a viable method for determining 
the IgG A33 hFab’ macromolecule heterogeneity state. Of particular interest, Figures 
(3, A and B) showed that the IgG A33 hFab’ macromolecule narrow in distribution 
sizes when changing the concentrations among 0.5 mg/ml and 1 mg/ml by using 
both 13° forwardscatter and 173° backscatter angles. The hydrodynamic diameters 
for the IgG A33 hFab’ macromolecule confirmed from Figure (3-A) that 0.5 mg/ml 
had ~ 3 nm and 1 mg/ml had ~ 3.5 nm in size. Also, the results of IgG A33 hFab’ 
macromolecule in Figure (3-B) proved that 0.5 mg/ml had ~ 2.4 nm and 1 mg/ml had 
~ 1.9 nm in size. These findings indicate that the IgG A33 hFab’ macromolecule with 
PBS buffer was pure and free of aggregated particles. Furthermore, the state of 
aggregated particles and turbidity state was shown regarding IgG A33 hFab' 
macromolecule with isopropyl alcohol preparation in the Appendix section, (Figures 1 
and 2).    
On the other hand, Figures (3, C and D) gave more information concerning the 
diffusion coefficients (D20,w) using 13° forwardscatter and 173° Backscatter angles. 
The lower diffusion coefficient correlated with no aggregation of IgG A33 hFab’ 
macromolecule. The diffusion coefficient results confirmed from Figure (3-C) that 0.5 
mg/ml had ~ 6.9 ×10-7 (%²
'
) and 1 mg/ml had 5.9 ×10-7 (%²
'
). Further, the results of 
Figure (3-D) illustrated that 0.5 mg/ml had ~ 7.3 ×10-7 (%²
'
) and 1 mg/ml had 9.5 ×10-7 
(%²
'
). Together these results provide important insight, that there is no evidence of 










       3.3 Molecular weight measurements  
 




Figure 4: SDS-PAGE determination of IgG A33 hFab’ molecular weight (M.wt) in the 
range of 10 – 250 kDa as a marker lane. A reducing agent called 2-mercaptoethanol 
was used in lanes (1,2 and 3) with different concentrations. Lane (4) was run without 
applying 2-mercaptoethanol, on a 12% gel (30 μl/well) stained with InstantBlue® 
Coomassie protein stain. The false colour in this plot was created using ImageJ 
software (Rasband 2011).    
 
 For the molecular weight measurements of the IgG A33 hFab' sodium dodecyl 
sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) was first used. Figure 4 
presents the results obtained before and after applying 2-Mercaptoethanol with a 
series of concentrations in lanes (1,2 and 3). It is obvious from Figure 4 that the 





In contrast, line 4 showed the molecular weight was ~ 48 kDa. The SDS-PAGE 
experiment confirmed is consistent with that of Lu et al. (2008) experimental results 
on “solution conformation of antibody fragments” study, which showed that the 
Human g1 Fab’ molecular weight is 48 kDa, as well. Since the number of cystine 
residues in IgG A33 hFab’ macromolecule are 11 residues (King et al. 2001), the 
disulfide bonds acting as a bridge between the heavy and light chains. Interestingly, 
the most striking result to emerge is that the using of reducing conditions like 2-
mercaptoethanol, will break the disulfide bonds and make the molecular weight lower 
as shown in lanes 1,2 and 3. Therefore, as shown in lane (4), the IgG A33 hFab’ 
macromolecule is ~ 48 kDa, which means a monomeric macromolecule state. The 
next step was to perform sedimentation equilibrium analysis to measure the 






























Figure 5: Sedimentation equilibrium of HSA, 2 methods of analysis are used in the 
SEDFIT-MSTAR program– the M* extrapolation method (A and B) and the hinge 
method (C and D) (Schuck et al. 2014). A & C are using interference optics and B & 
D are using absorption optics at 280nm. A loading concentration of 0.6 mg.ml-1 was 



































































































Figure 6: Sedimentation equilibrium analysis of IgG A33 hFab’ using SEDFIT-
MSTAR (Schuck et al. 2014). Using (A) the M* extrapolation method and (B) hinge 
point method, with concentrations expressed in fringe units, a loading concentration 
of 0.62 mg/ml was used.  
 
Sedimentation equilibrium was employed to assess the HSA and IgG A33 hFab’ 
macromolecules apparent molecular weight (Mw,app) using SEDFIT-MSTARv1 
software (Schuck et al. 2014). The diagrams in Figures (5 and 6), clarifies the 
determination of the apparent molecular weight of the HSA and IgG A33 hFab’ 
macromolecules at 0.60 mg/ml and 0.62 mg/ml, respectively. At these low 
concentrations, non-ideality effects were considered to be small. Accordingly, the 
absorbance results in Figure (5-B+D) revealed that the HSA molecular weight 
utilising M* method is ≈ (70.9 ± 0.3) kDa and the Mw,app (hinge) method is ≈ (70.5 ± 
0.3) kDa, consistent with a monomeric protein (Belinskaia et al. 2021). With the 
interference results a slightly higher molecular weight was obtained: Mw,app is ≈ (86.0 
± 4.0) kDa with both the M* and hinge methods.     
 
For IgG A33 hFab’ the interference data in Figure (6-A+B), showed that IgG A33 
hFab’ molecular weight employing M* method is ≈ (51.9 ± 1.4) kDa and hinge 
method is ≈ (49.9 ± 1.4) kDa, and similar results were obtained with UV absorption 

























































































































Figure 7: The c (s) profile for IgG A33 hFab’ macromolecule as a function of the 
sedimentation coefficient distribution (s20,w) at 7 serial dilutions, starting from 1.2 
mg/ml to 0.02 mg/ml, for both interference measurements ( ) and the absorbance 




Figure 8: Reciprocal diagrams of s20,w (s-1 or Svedberg-1) versus the concentration of 
IgG A33 hFab’ macromolecule in (mg/ml), and with extrapolation to zero 
concentration at 20.0 °C. so20,w = 3.8 S (interference) and 4.1 S (absorbance).  
 
Sedimentation Velocity (SV) was applied to assess the presence of aggregates and 
dimers using the interference and absorbance optical methods. As noticed from 
Figure (7), the c (s) profile versus s20,w was utilised for both Rayleigh interference 
and the absorbance methods. Accordingly, the results of IgG A33 hFab’ 
macromolecule is pure and free of aggregated particles. This was evidenced by the 
existence of one peak in the interference and absorbance data for a series of 
concentrations starting from 1.12 mg/ml to 0.02 mg/ml.  
 
Afterwards, the illustration in Figure (8), shows the reciprocal of IgG A33 hFab’ 
macromolecule sedimentation coefficient (1/s20,w), which generated by the 
extrapolation to zero concentration, for eliminating the non-ideality against the 
concentration in mg/ml. The extrapolated 1/so20,w values of the interference and 































gives corresponding so20,w values of 3.79 Svedberg (interference) and 4.07 Svedberg 
(absorbance), in agreement with Carrasco et al. (1999). It seems that the IgG A33 
hFab’ is monomeric, homogeneous and free of aggregated macromolecules by the 
existing of one peak for both interference and absorbance data. Also, since the state 
of the IgG A33 hFab’ macromolecule was confirmed monomeric using SDS-PAGE 
method, therefore, the monomeric state will allow us to investigate more using the 
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Figure 9: Sedimentation velocity (SV) analysis for HSA ( ), IgG A33 hFab’ ( ) 
and a mixture of the two ( ) at differing mixing ratios. Interference and absorbance 
(280 nm) records shown.  
 
A further application of SV was to investigate the possible interactions between the 
HSA and the IgG A33 hFab’ macromolecules. HSA and IgG A33 hFab’ using both 
interference and absorbance optical systems with different concentrations, which are 
0.6 mg/ml (Figure 9-A), 1.2 mg/ml (Figure 9-B) and 2.4 mg/ml (Figure 9-C). Only one 
peak is seen in the mixtures suggesting a possible interaction, although this single 
peak has a sedimentation coefficient lower than the HSA – if an interaction has taken 
place, the complex must have a much higher asymmetry to explain the slower 
sedimentation coefficient (as normally a larger molecule would sediment faster).   
The appearance of a single peak may however possibly be explained by the 
Johnston and Ogston (1946) effect. The faster moving HSA may be being slowed 
down by having to move through the slower moving IgG A33 hFab’. According to the 
estimation of refractive increment boundaries, there is an apparent rise in the 
quantity of the less rapidly sedimenting composition with a corresponding reduction 
in the amount of other compositions. The impact is minimal at low protein 
concentrations, but it constantly rises as the concentration is increased. This is 
























Figure 10: Ellipsoidal (prolate) representation of the IgG A33 hFab’ macromolecule 
from the hydrodynamic analysis generated using ELLIPS 1 software. The axial ratio 




























Figure 11: The intrinsic viscosity of human serum albumin plot using multiple 
viscosity functions. [ ]: is the reduced viscosity (ηred) fitted by Huggins equation; [
] is the fitting of Solomon-Ciuta estimates equation ([η]); [ ] is the inherent 
viscosity (ηinh) fitted by Kraemer equation with a linear extrapolation to zero 
concentration.     
 
Figure 12: Ellipsoidal (prolate) representation of the HSA macromolecule from the 
hydrodynamic analysis generated using ELLIPS 1 software. The axial ratio a/b = 2.7 
and b/c= 1.00.  
Table 2: Summary of IgG A33 hFab’ and HSA hydrodynamic properties.  
Macromolecules properties IgG A33 hFab’ HSA  
 v-bar 0.731 ml/g  0.736 ml/g  
  d  0.3583 g/g  0.4117 g/g 
 vs 1.09 ml/g  1.15 ml/g  
ℇ280  1394 ml.g-1.cm-1  526 ml.g-1.cm-1 





𝝊 3.62 3.47 
a/b (prolate) 2.9 2.7 
so20,w 3.95 N.D 
Mw (SDS-PAGE) 48 kDa N.D 
Mw (Sedimentation equilibrium)  50.9 kDa 70.7 kDa 
 
The Ostwald (U-tube) capillary viscometer is a fundamental instrument for validation 
of the IgG A33 hFab’ and HSA macromolecules shape and to determine their 
intrinsic viscosities. The results shown that HSA has ~ the same intrinsic viscosity as 
IgG A33 hFab’ calculated using (equation 3.2 for the HSA), with an average value 
getting from using equations (3.2.3.4 and 3.5) for the HSA (see Materials and 
methods section). According to Figures 10 and 12, the ellipsoidal (prolate) 
representation with a/b seems to be similar: the shape factor of the HSA is 
approximately the same as with IgG A33 hFab’, which were found from ELLIPS1 
software (see Figures 10 and 12). From table 2, the extinction coefficient of IgG A33 
hFab’ has a higher value than the HSA, this is referred to the existing of highly 
amounts of tryptophan and tyrosine amino acid residues. The PERKINS software 
was employed and gave the partial specific volume (v-bar) and hydration (d) values 
of both macromolecules depending on their amino acid sequences, which shown in 
table 2, as well. Further, the intrinsic viscosity of HSA was calculated after measuring 
a series of HSA concentrations at a constant temperature of (20.00 ±0.01) °C. 
However, the non-ideality was eliminated by extrapolation to zero concentrations 












4. Conclusions and Future Work 
 
              In conclusion, this experimental study has set out to characterise the IgG 
A33 hFab’ and human serum albumin macromolecules using several hydrodynamic 
techniques, alongside the investigation of possible interactions between them. The 
investigation by both dynamic light scattering, and sedimentation velocity has 
revealed that IgG A33 hFab’ can be used PBS buffer as an aqueous solvent, which 
is homogeneous and free of aggregated particles. This study has found that the IgG 
A33 hFab’ molecular weight is ~ 48- 50 kDa and is in the monomeric state using the 
SDS-PAGE and SE methods. Application of reducing conditions namely 2-
mercaptoethanol reduces the M.wt from 48 kDa to 25 kDa, by the breakage in the 
disulfide bonds. The HSA molecular weight is 71 kDa through applying the SE 
method, as well and sedimentation velocity also shows this to be homogeneous (one 
peak). The SV results supported the SDS-PAGE and SE results, since the IgG A33 
hFab’ and HSA are monomeric and homogenous by the existence of one peak for a 
series of concentrations. The SV method was also used as a for a preliminary 
investigation in the possible interaction between HSA and IgG A33. The existence of 
a single peak in the mixture may be due to an interaction or due to a phenomenon 
known as the Johnston-Ogston effect: this is a matter for follow up/ further 
investigation. This means if there is an interaction this will limit the use of IgG A33 
hFab’ as a biotherapeutic drug. Further experimental investigations are therefore 
needed using Sedimentation Equilibrium to verify the Sedimentation Velocity findings 
concerning the potential interaction between HSA and IgG A33 hFab’ 
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Appendix: Investigation of the effect of a non-aqueous 




Figure (A1): Representative selection of Eppendorf tubes showing the increasing in 
turbidity or aggregation of the IgG A33 hFab’ with isopropyl alcohol starting from tube 




Figure (A2): Aggregation of A33 hFab’ in isopropyl alcohol shown by dynamic light 
scattering method. Plot (A2-A) represents multiple measurements of the filtered and 

































un-filtered samples using 173° backscatter angle and (A2-B) clarifying the multiple 
measurements of the filtered and un-filtered sample using 13° forwardscatter angle. 
 
 
 
  
